Can fasting two days a week slow kidney cancer? a new trial tests the idea

NCT ID NCT07714018

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This trial compares two weight-loss approaches—daily calorie restriction versus 5:2 intermittent fasting—in people with small kidney tumors who are being monitored rather than treated immediately. The goal is to see which program helps patients lose more weight and whether that might reduce the risk of tumor growth. Participants will follow their assigned diet for six months with coaching and self-monitoring.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
two weight-loss programs: intermittent fasting (5:2 diet) and continuous calorie restriction
What this could lead to
If successful, this could show that intermittent fasting is a better weight-loss strategy than daily calorie cutting for kidney cancer patients, potentially helping to slow cancer progression.
What could go wrong
This is a very small early-stage trial with only 20 participants, so results may not apply to all patients. Weight loss may not directly affect tumor growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York, 14263, United States

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.